Cardiologists mark Australian first with Boston Scientific’s intracoronary imaging system

MedTech & Diagnostics News: Percutaneous coronary intervention (PCI) has faced substantial complications and failure rates, despite advances in medical devices and techniques. Gosford Private Hospital in New South Wales achieved a notable milestone by successfully performing Australia’s first procedure using the Boston Scientific Avvigo+ system, led by interventional cardiologists Associate Professor Tom Ford and Dr Prajith Jeyaprakash.

The introduction of intracoronary imaging (ICI) has dramatically improved understanding of the mechanical and technical factors that contribute to both successful and failed PCI, becoming essential in complex transcatheter interventions.

Recognising the importance of intracoronary imaging, the American College of Cardiology Committee on Clinical Practice Guidelines recommended its routine use in PCI procedures last year.

The Avvigo+ system is the first intravascular ultrasound (IVUS) imaging system equipped with artificial intelligence (AI) software, known as Automated Lesion Assessment. This innovative technology automates key procedural steps, provides precise vessel measurements, and reduces procedure time by acquiring IVUS images at a faster speed. Additionally, it offers enhanced guidance by generating a physiology graph, effectively creating a roadmap to treat diseased coronary arteries.

Pat Callanan, Business Unit Director ANZ, Interventional Cardiology at Boston Scientific, said “The Avvigo+ Multi-Modality Guidance System aims to give cardiac cath labs more options in the space of imaging and physiology. Advancements in healthcare technology and treatments are crucial for improving patient outcomes and enhancing the quality of care.”

In a global collaboration with Boston Scientific, GE HealthCare is positioning its Allia IGS Pulse at the centre of the cath lab, making it compatible with various hardware from device developers, including the Avvigo+.

The company’s AutoRight Plus AI-powered software will work with the Avvigo+ system’s automated lesion assessment capabilities. It uses intravascular ultrasound imaging catheters and machine learning algorithms to automatically identify blood vessel borders and diameters for precise stent placements.

The Avvigo+ system is not currently approved on the Australian Register of Therapeutic Goods (ARTG).

In reimagining healthcare, Health Industry Hub^TM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.